Interestingly, patients previously treated with BRAF inhibitors had a worse response in terms of tumor size and progression-free survival, suggesting that BRAF inhibition-resistant mechanisms activate cancer-related reprogramming of the cell in such a way that MEK inhibitor sensitivity is lower. Here, MAP2K7 is linked to neoplasm.